Press releases
Browse Canadian-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
$1.5 million boost to endowed chair from GSK positions U of A to expand leadership in virology research
New investment in long-standing partnership will help create jobs and attract top talent in burgeoning biotech industry, says founding chair
-
GSK Canada submits respiratory syncytial virus (RSV) vaccine candidate for regulatory review
GSK Canada submits respiratory syncytial virus (RSV) vaccine candidate for regulatory review
-
GSK welcomes agreement with the Government of Canada for the provision of pandemic and seasonal influenza vaccines
GSK welcomes agreement with the Government of Canada for the provision of pandemic and seasonal influenza vaccines
-
Regulatory submission for GSK’s daprodustat accepted into Health Canada review
GSK announces that Health Canada has accepted into review the New Drug Submission (NDS) for daprodustat
-
GSK Canada unveils new head office, embracing a hybrid working model centred around individual and collective performance and personal well-being
GSK Canada unveils new head office, embracing a hybrid working model
-
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine
-
GSK announces independent Consumer Healthcare company is to be called Haleon
GSK announces independent Consumer Healthcare company is to be called Haleon
-
GSK announces additional purchase agreements with the Government of Canada for COVID-19 monoclonal antibody therapy, Sotrovimab
GSK announces additional purchase agreements with the Government of Canada for COVID-19 monoclonal antibody therapy, Sotrovimab
-
GSK’s JEMPERLI (dostarlimab for injection) approved in Canada as an anti-PD-1 therapy for recurrent or advanced endometrial cancer
GSK’s JEMPERLI (dostarlimab for injection) approved in Canada
-
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
-
SHINGRIX approved in Canada for adults at increased risk of shingles due to immunodeficiency or immunosuppression
SHINGRIX approved in Canada for adults at increased risk of shingles due to immunodeficiency or immunosuppression
-
For the third consecutive year in a row GSK is named one of Canada’s Top 100 Employers
For the third consecutive year in a row GSK is named one of Canada’s Top 100 Employers
-
NUCALA (mepolizumab) the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults with chronic rhinosinusitis with nasal polyps (CRSwNP)
NUCALA (mepolizumab) the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults
-
VOLUNTARILY RECALL OF TUMS EXTRA STRENGTH (750MG) ASSORTED BERRY 100CT AND ROLL 3X8CT
VOLUNTARILY RECALL OF TUMS EXTRA STRENGTH (750MG) ASSORTED BERRY 100CT AND ROLL 3X8CT
-
GSK announces purchase agreement with the Government of Canada for COVID-19 monoclonal antibody therapy, sotrovimab
GSK announces purchase agreement with the Government of Canada for COVID-19 monoclonal antibody therapy, sotrovimab
-
Important information on Advil Cold & Sinus Daytime / Nighttime Convenience Pack
Important information on Advil Cold & Sinus Daytime / Nighttime Convenience Pack
-
Changing attitudes to vaccination post-COVID suggest investing in our own health is a key priority for many Canadians
Changing attitudes to vaccination post-COVID suggest investing in our own health is a key priority for many Canadians
-
NUCALA (mepolizumab) approved in Canada as the first and only biologic treatment for adults with hypereosinophilic syndrome
NUCALA (mepolizumab) approved in Canada as the first and only biologic treatment for adults with hypereosinophilic syndrome
-
GSK receives authorization under Health Canada’s Interim Order for Sotrovimab for Injection to treat COVID-19 in high-risk adults and adolescents
GSK receives authorization under Health Canada’s Interim Order for Sotrovimab for Injection to treat COVID-19 in high-risk adults and
-
BENLYSTA now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients
BENLYSTA now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients
